Trends in incidence of treated end-stage renal disease, overall and by primary renal disease, in persons aged 20-64 years in Europe, Canada and the Asia-Pacific region, 1998-2002

Nephrology

Volumn 12, Issue 5, 2007, Pages 520-527

  Stewart, John H ^a   McCredie, Margaret R E ^a   Williams, Sheila M ^a   Jager, Kitty J ^b   Trpeski, Lilyanna ^c   McDonald, Stephen P ^d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Canadian Organ Replacement Register   (Canada)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Diabetic nephropathy; End stage renal disease; Incidence trend; Prevention; Primary renal disease; Renoprotective treatment

Indexed keywords

ADULT; ARTICLE; ASIA; CANADA; CONTROLLED STUDY; EUROPE; FEMALE; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGE DISTRIBUTION; ASIA; CANADA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; EUROPE; GLOMERULONEPHRITIS; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PACIFIC ISLANDS; POISSON DISTRIBUTION; POLYCYSTIC KIDNEY DISEASES;

EID: 34548453568     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00830.x     Document Type: Article

References (44)

1. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001 357 : 1601 8.
2. Wolfe RA, Held PJ, Hulbert-Shearon TA, Agodoa LYC, Port FK. A critical examination of trends in outcome over the last decade. Am. J. Kidney Dis. 1998 32 (Suppl 4 S9 15.
3. Stewart JH, McCredie MRE, Williams SM, McDonald SP. Interpreting incidence trends for treated end-stage renal disease: Implications for evaluating disease control in Australia. Nephrology 2004 9 : 238 46.
4. Stengel B, Billon S, van Dijk PCW et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol. Dial. Transplant. 2003 18 : 1824 33.
5. van Dijk PCW, Jager KJ, Stengel B, Grönhagen-Riska C, Feest TG, Briggs JD. Renal replacement therapy for diabetic end-stage renal disease: Data from ten registries in Europe (1991-2000). Kidney Int. 2005 67 : 1489 99.
6. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD : National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
7. Wakai K, Nakai S, Kikuchi K et al. Trends in incidence of end-stage renal disease in Japan, 1983-2000: Age-adjusted and age-specific rates by gender and cause. Nephrol. Dial. Transplant. 2004 19 : 2044 52.
8. Perneger TV, Klag MJ, Feldman HI, Whelton PK. Projections of hypertension-related renal disease in middle-aged residents of the United States. JAMA 1993 269 : 1272 7.
9. The ESRD Incidence Study Group. Geographic, ethnic, age-related and temporal variation in the incidence of end-stage renal disease in Europe, Canada and the Asia-Pacific region, 1998-2002. Nephrol. Dial. Transplant. 2006 21 : 2178 83.
10. Roderick PJ, Raleigh VS, Hallam L, Mallick NP. The need and demand for renal replacement therapy in ethnic minorities in England. J. Epidemiol. Community Health 1996 50 : 334 9.
11. Stewart JH, McCredie MRE, McDonald SP. Incidence of end-stage renal disease in overseas-born, compared with Australian-born, non-indigenous Australians. Nephrology 2004 9 : 247 52.
12. Maisonneuve P, Agodoa L, Gellert R et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. Am. J. Kidney Dis. 2000 35 : 157 65.
13. Stewart JH, McCredie MRE, Williams SM et al. The enigma of hypertensive ESRD: Observations on incidence and trends in 18 European, Canadian, and Asian-Pacific populations, 1998-2002. Am. J. Kidney Dis. 2006 48 : 183 91.
14. The ESRD Incidence Study Group. Divergent trends in the incidence of end-stage renal disease due to type 1 and type 2 diabetes in Europe, Canada and Australia during 1998-2002. Diabet. Med. 2006 23 : 1364 9.
15. Muntner P, Coresh J, Powe NR, Klag MJ. The contribution of increased diabetes prevalence and improved myocardial infarction and stroke survival to the increase in treated end-stage renal disease. J. Am. Soc. Nephrol. 2003 14 : 1568 77.
16. Termorshuizen F, Korevaar JC, Dekker FW et al. for the NECOSAD Study Group. Time trends in initiation and dose of dialysis in end-stage renal disease patients in The Netherlands. Nephrol. Dial. Transplant. 2003 18 : 552 8.
17. Zmirou D, Benhamou PY, Cordonnier D et al. Diabetes mellitus prevalence among dialysed patients in France (UREMIDIAB Study). Nephrol. Dial. Transplant. 1992 7 : 1092 7.
18. Onkamo P, Väänänen S, Karvonen M, Tuomilehto J. Worldwide increase in incidence of type 1 diabetes - analysis of the data on published incidence trends. Diabetologia 1999 42 : 1395 403.
19. Harvey JN, Rizvi K, Craney L, Messenger J, Shah R, Meadows PA. Population-based survey and analysis of trends in the prevalence of diabetic nephropathy in type 1 diabetes. Diabet. Med. 2001 18 : 998 1002.
20. Finne P, Reunanen A, Stenman S, Groop P-H, Grönhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005 294 : 1782 7.
21. Parving H-H, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: Diabetic nephropathy. Curr. Opin. Nephrol. Hypertens. 2001 10 : 515 22.
22. Simon P, Ramee M-P, Boulahrouz R et al. Epidemiologic data of primary glomerular diseases in western France. Kidney Int. 2004 66 : 905 8.
23. Chadban SJ, Atkins RC. Glomerulonephritis. Lancet 2005 365 : 1797 806.
24. Torres VE, Velosa JA, Holley KE, Kelalis PP, Stickler GB, Kurtz SB. The progression of vesicoureteral reflux nephropathy. Ann. Intern. Med. 1980 92 : 776 84.
25. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N. Engl. J. Med. 1982 307 : 652 9.
26. Craig JC, Irwig LM, Knight JF, Roy LP. Does treatment of vesicoureteric reflux in childhood prevent end-stage renal disease attributable to reflux nephropathy? Pediatrics 2000 105 : 1236 41.
27. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int. 2005 67 : 1684 91.
28. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care 1998 21 : 518 24.
29. Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000 23 : 1278 83.
30. Dunstan DW, Zimmet PZ, Welborn TA et al. On behalf of the AusDiab Steering Committee. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002 25 : 829 34.
31. Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003 289 : 76 9.
32. Meisinger C, Heier M, Doering A, Thorand B, Loewel H for the KORA Group. Prevalence of known diabetes and anti-diabetic therapy between 1984/1985 and 1999/2000 Southern Germany. Diabetes Care 2004 27 : 2985 7.
33. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006 69 : 913 19.
34. Nicholls K. ACE inhibitor treatment in diabetic nephropathy. Nephrology 2006 11 (Suppl 1 S79 91.
35. Nicholls K. Angiotensin II antagonists. Nephrology 2006 11 (Suppl 1 S92 7.
36. Leibson CL, Williamson DF, Melton LJ et al. Temporal trends in BMI among adults with diabetes. Diabetes Care 2001 24 : 1584 9.
37. Bosma RJ, Krikken JA, van der Heide JJ, de Jong PE, Navis GJ. Obesity and renal hemodynamics. Contrib. Nephrol. 2006 151 : 184 202.
38. Fioretto P, Mauer M, Brocco E et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996 39 : 1569 76.
39. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet. Med. 1997 14 (Suppl 5 S1 85.
40. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA 2002 287 : 2519 27.
41. Dyck RF. Tracking ancient pathways to a modern epidemic: Diabetic end-stage renal disease in Saskatchewan aboriginal people. Kidney Int. 2005 67 (Suppl 97 S53 7.
42. Hoy WE, Wang Z, Baker PRA, Kelly AM. Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian Aboriginal community. Kidney Int. 2003 63 (Suppl 83 S66 73.
43. Narva AS. The spectrum of kidney disease in American Indians. Kidney Int. 2003 63 (Suppl 83 S3 7.
44. Dyck RF. Mechanisms of renal disease in indigenous populations: Influences at work in Canadian indigenous peoples. Nephrology 2001 6 : 3 7.